Skip to main content
Top
Published in: Medicine, Health Care and Philosophy 3/2014

01-08-2014 | Scientific Contribution

The value and pitfalls of speculation about science and technology in bioethics: the case of cognitive enhancement

Authors: Eric Racine, Tristana Martin Rubio, Jennifer Chandler, Cynthia Forlini, Jayne Lucke

Published in: Medicine, Health Care and Philosophy | Issue 3/2014

Login to get access

Abstract

In the debate on the ethics of the non-medical use of pharmaceuticals for cognitive performance enhancement in healthy individuals there is a clear division between those who view “cognitive enhancement” as ethically unproblematic and those who see such practices as fraught with ethical problems. Yet another, more subtle issue, relates to the relevance and quality of the contribution of scholarly bioethics to this debate. More specifically, how have various forms of speculation, anticipatory ethics, and methods to predict scientific trends and societal responses augmented or diminished this contribution? In this paper, we use the discussion of the ethics of cognitive enhancement to explore the positive and negative contribution of speculation in bioethics scholarship. First, we review and discuss how speculation has relied on different sets of assumptions regarding the non-medical use of stimulants, namely: (1) terminology and framing; (2) scientific aspects such as efficacy and safety; (3) estimates of prevalence and consequent normalization; and (4) the need for normative reflection and regulatory guidelines. Second, three methodological guideposts are proposed to alleviate some of the pitfalls of speculation: (1) acknowledge assumptions more explicitly and identify the value attributed to assumptions; (2) validate assumptions with interdisciplinary literature; and (3) adopt a broad perspective to promote more comprehensive reflection. We conclude that, through the examination of the controversy about cognitive enhancement, we can employ these methodological guideposts to enhance the value of contributions from bioethics and minimize potential epistemic and practical pitfalls in this case and perhaps in other areas of bioethical debate.
Footnotes
1
Our own reflection was part of a project examining the legal, ethical and social consequences of memory technologies in an effort to engage in meta-ethical questions about bioethics itself. Some of the authors of this paper have directly intervened in this debate and therefore take a reflexive stance on their own scholarship and the claims made in their contributions.
 
2
Throughout debates about the non-medical use of stimulants, a further complicating factor has been the evolving definition of the term “cognitive enhancement”. Ferrari et al. (2012) identify these shifts in meaning by looking at the history of human enhancement: “the term ‘cognitive enhancement’ was originally used to describe the treatment of disease-associated cognitive impairment…the meaning of the term was subsequently broadened to encompass the use of interventions for mild cognitive impairment (MCI) (…) More recently ‘cognitive enhancement’ has been applied to interventions in normal ageing processes and in ‘healthy’ people for non-medical purposes” (Ferrari et al. 2012).
 
Literature
go back to reference Am, T.G. 2011. Trust in nanotechnology? On trust as analytical tool in social research on emerging technologies. Nanoethics 5(1): 15–28.CrossRef Am, T.G. 2011. Trust in nanotechnology? On trust as analytical tool in social research on emerging technologies. Nanoethics 5(1): 15–28.CrossRef
go back to reference Beauchamp, T., and J. Childress. 2009. Principles of biomedical ethics. Oxford: Oxford University Press. Beauchamp, T., and J. Childress. 2009. Principles of biomedical ethics. Oxford: Oxford University Press.
go back to reference Bell, S., J. Lucke, and W. Hall. 2012. Lessons for enhancement from the history of cocaine and amphetamine use. AJOB Neuroscience 3(2): 24–29.CrossRef Bell, S., J. Lucke, and W. Hall. 2012. Lessons for enhancement from the history of cocaine and amphetamine use. AJOB Neuroscience 3(2): 24–29.CrossRef
go back to reference Boot, B.P., B. Partridge, and W. Hall. 2011. Letter to the editor: Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase 18(3): 181–184.CrossRef Boot, B.P., B. Partridge, and W. Hall. 2011. Letter to the editor: Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase 18(3): 181–184.CrossRef
go back to reference Bostrom, N., and A. Sandberg. 2009. Cognitive enhancement: Methods, ethics, regulatory challenges. Science and Engineering Ethics 15(3): 311–341.CrossRef Bostrom, N., and A. Sandberg. 2009. Cognitive enhancement: Methods, ethics, regulatory challenges. Science and Engineering Ethics 15(3): 311–341.CrossRef
go back to reference Brey, P. 2012. Anticipatory ethics for emerging technologies. Nanoethics 6(1): 1–13.CrossRef Brey, P. 2012. Anticipatory ethics for emerging technologies. Nanoethics 6(1): 1–13.CrossRef
go back to reference Caplan, A., and C. Elliott. 2004. Is it ethical to use enhancement technologies to make us better than well? PLoS Medicine 1(3): e52.CrossRef Caplan, A., and C. Elliott. 2004. Is it ethical to use enhancement technologies to make us better than well? PLoS Medicine 1(3): e52.CrossRef
go back to reference Carter, A., P. Bartlett, and W. Hall. 2009. Scare-mongering and the anticipatory ethics of experimental technologies. American Journal of Bioethics 9(5): 47–48.CrossRef Carter, A., P. Bartlett, and W. Hall. 2009. Scare-mongering and the anticipatory ethics of experimental technologies. American Journal of Bioethics 9(5): 47–48.CrossRef
go back to reference Colander, D., H. Follmer, A. Haas, M.D. Goldberg, K. Juselius, A. Kirman, T. Lux, and B. Sloth. 2009. The financial crisis and the systemic failure of academic economics. Copenhagen: University of Copenhagen Department of Economics. Colander, D., H. Follmer, A. Haas, M.D. Goldberg, K. Juselius, A. Kirman, T. Lux, and B. Sloth. 2009. The financial crisis and the systemic failure of academic economics. Copenhagen: University of Copenhagen Department of Economics.
go back to reference Connemann, B.J. 2003. Donepezil and flight simulator performance: Effects on retention of complex skills. Neurology 61(5): 721. author reply 721.CrossRef Connemann, B.J. 2003. Donepezil and flight simulator performance: Effects on retention of complex skills. Neurology 61(5): 721. author reply 721.CrossRef
go back to reference de Jongh, R., I. Bolt, M. Schermer, and B. Olivier. 2008. Botox for the brain: Enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neuroscience and Biobehavioral Reviews 32(4): 760–776.CrossRef de Jongh, R., I. Bolt, M. Schermer, and B. Olivier. 2008. Botox for the brain: Enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neuroscience and Biobehavioral Reviews 32(4): 760–776.CrossRef
go back to reference Dees, R.H. 2004. Slippery slopes, wonder drugs, and cosmetic neurology: The neuroethics of enhancement. Neurology 63(6): 951–952.CrossRef Dees, R.H. 2004. Slippery slopes, wonder drugs, and cosmetic neurology: The neuroethics of enhancement. Neurology 63(6): 951–952.CrossRef
go back to reference Dewey, J. 1922. Human nature and conduct: An introduction to social psychology. New York: Holt. Dewey, J. 1922. Human nature and conduct: An introduction to social psychology. New York: Holt.
go back to reference Dresler, M., A. Sandberg, K. Ohla, C. Bublitz, C. Trenado, A. Mroczko-Wasowicz, S. Kuhn, and D. Repantis. 2013. Non-pharmacological cognitive enhancement. Neuropharmacology 64: 529–543.CrossRef Dresler, M., A. Sandberg, K. Ohla, C. Bublitz, C. Trenado, A. Mroczko-Wasowicz, S. Kuhn, and D. Repantis. 2013. Non-pharmacological cognitive enhancement. Neuropharmacology 64: 529–543.CrossRef
go back to reference Evans, J.H. 2002. Playing God? Human genetic engineering and the rationalization of public bioethical debate. Chicago: Chicago University Press. Evans, J.H. 2002. Playing God? Human genetic engineering and the rationalization of public bioethical debate. Chicago: Chicago University Press.
go back to reference Durand, G. 1999. Introduction générale à la bioéthique: Histoire, concepts et outils. Fides-Cerf: Montréal. Durand, G. 1999. Introduction générale à la bioéthique: Histoire, concepts et outils. Fides-Cerf: Montréal.
go back to reference Farah, M.J. 2011. Overcorrecting the neuroenhancement discussion. Addiction 106(6): 1190. author reply 1190–1191. Farah, M.J. 2011. Overcorrecting the neuroenhancement discussion. Addiction 106(6): 1190. author reply 1190–1191.
go back to reference Farah, M.J., J. Illes, R. Cook-Deegan, H. Gardner, E. Kandel, P. King, E. Parens, B. Sahakian, and P.R. Wolpe. 2004. Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience 5(5): 421–425.CrossRef Farah, M.J., J. Illes, R. Cook-Deegan, H. Gardner, E. Kandel, P. King, E. Parens, B. Sahakian, and P.R. Wolpe. 2004. Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience 5(5): 421–425.CrossRef
go back to reference Ferrari, A., C. Coenen, and A. Grunwald. 2012. Visions and ethics in current discourse on human enhancement. Nanoethics 6(3): 215–229.CrossRef Ferrari, A., C. Coenen, and A. Grunwald. 2012. Visions and ethics in current discourse on human enhancement. Nanoethics 6(3): 215–229.CrossRef
go back to reference Fins, J.J. 2008. A leg to stand on: Sir William Osler and Wilder Penfield’s “neuroethics”. American Journal of Bioethics 8(1): 37–46.CrossRef Fins, J.J. 2008. A leg to stand on: Sir William Osler and Wilder Penfield’s “neuroethics”. American Journal of Bioethics 8(1): 37–46.CrossRef
go back to reference Forlini, C., and E. Racine. 2009a. Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: perspectives of key stakeholders. Neuroethics 2(3): 163–177.CrossRef Forlini, C., and E. Racine. 2009a. Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: perspectives of key stakeholders. Neuroethics 2(3): 163–177.CrossRef
go back to reference Forlini, C., and E. Racine. 2009b. Disagreements with implications: Diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Medical Ethics 10. Forlini, C., and E. Racine. 2009b. Disagreements with implications: Diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Medical Ethics 10.
go back to reference Forlini, C., and E. Racine. 2012. Stakeholder perspectives and reactions to “academic” cognitive enhancement: Unsuspected meaning of ambivalence and analogies. Public Understanding of Science 21(5): 606–625.CrossRef Forlini, C., and E. Racine. 2012. Stakeholder perspectives and reactions to “academic” cognitive enhancement: Unsuspected meaning of ambivalence and analogies. Public Understanding of Science 21(5): 606–625.CrossRef
go back to reference Forlini, C., and E. Racine. 2013. Does the cognitive enhancement debate call for a renewal of the deliberative role of bioethics? In Cognitive enhancement: An interdisciplinary perspective, ed. E. Hildt, and A. Franke, 173–186. New York: Springer.CrossRef Forlini, C., and E. Racine. 2013. Does the cognitive enhancement debate call for a renewal of the deliberative role of bioethics? In Cognitive enhancement: An interdisciplinary perspective, ed. E. Hildt, and A. Franke, 173–186. New York: Springer.CrossRef
go back to reference Fortun, M. 2005. For an ethics of promising, or: A few kind words about James Watson. New Genetics & Society 24(2): 157–174.CrossRef Fortun, M. 2005. For an ethics of promising, or: A few kind words about James Watson. New Genetics & Society 24(2): 157–174.CrossRef
go back to reference Franke, A., C. Bonertz, M. Christmann, S. Engeser, and K. Lieb. 2012. Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: A pilot study. AJOB Primary Research 3(1): 48–57.CrossRef Franke, A., C. Bonertz, M. Christmann, S. Engeser, and K. Lieb. 2012. Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: A pilot study. AJOB Primary Research 3(1): 48–57.CrossRef
go back to reference Greely, H., B. Sahakian, J. Harris, R.C. Kessler, M. Gazzaniga, P. Campbell, and M.J. Farah. 2008. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456(7223): 702–705.CrossRef Greely, H., B. Sahakian, J. Harris, R.C. Kessler, M. Gazzaniga, P. Campbell, and M.J. Farah. 2008. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456(7223): 702–705.CrossRef
go back to reference Hall, W., and J. Lucke. 2010. The enhancement use of neuropharmaceuticals: More scepticism and caution needed. Addiction 105(12): 2041–2043.CrossRef Hall, W., and J. Lucke. 2010. The enhancement use of neuropharmaceuticals: More scepticism and caution needed. Addiction 105(12): 2041–2043.CrossRef
go back to reference Hedgecoe, A. 2010. Bioethics and the reinforcement of socio-technical expectations. Social Studies of Science 40(2): 163–186.CrossRef Hedgecoe, A. 2010. Bioethics and the reinforcement of socio-technical expectations. Social Studies of Science 40(2): 163–186.CrossRef
go back to reference Heinz, A., R. Kipke, H. Heimann, and U. Wiesing. 2012. Cognitive neuroenhancement: False assumptions in the ethical debate. Journal of Medical Ethics 38(6): 372–375.CrossRef Heinz, A., R. Kipke, H. Heimann, and U. Wiesing. 2012. Cognitive neuroenhancement: False assumptions in the ethical debate. Journal of Medical Ethics 38(6): 372–375.CrossRef
go back to reference Henry, M., J.R. Fishman, and S.J. Youngner. 2007. Propranolol and the prevention of post-traumatic stress disorder: Is it wrong to erase the “sting” of bad memories? American Journal of Bioethics 7(9): 12–20.CrossRef Henry, M., J.R. Fishman, and S.J. Youngner. 2007. Propranolol and the prevention of post-traumatic stress disorder: Is it wrong to erase the “sting” of bad memories? American Journal of Bioethics 7(9): 12–20.CrossRef
go back to reference Illes, J., and E. Racine. 2005. Neuroethics: A dialogue on a continuum from tradition to innovation. American Journal of Bioethics 5(2): W3.CrossRef Illes, J., and E. Racine. 2005. Neuroethics: A dialogue on a continuum from tradition to innovation. American Journal of Bioethics 5(2): W3.CrossRef
go back to reference Iversen, L. 2006. Speed, ecstasy, ritalin: The science of amphetamines. Oxford: Oxford University Press. Iversen, L. 2006. Speed, ecstasy, ritalin: The science of amphetamines. Oxford: Oxford University Press.
go back to reference Jones, G. 2008. Neuroethics: Adrift from a clinical base. American Journal of Bioethics 8(1): 49–50.CrossRef Jones, G. 2008. Neuroethics: Adrift from a clinical base. American Journal of Bioethics 8(1): 49–50.CrossRef
go back to reference Jonsen, A.R. 1995. Casuistry: An alternative or complement to principles? Kennedy Institute of Ethics Journal 5(3): 237–251.CrossRef Jonsen, A.R. 1995. Casuistry: An alternative or complement to principles? Kennedy Institute of Ethics Journal 5(3): 237–251.CrossRef
go back to reference Jonsen, A.R., M. Siegler, and W.T. Winslade. 1998. Clinical ethics: A practical approach to ethical decisions in clinical medicine, 4th ed. New York: McGraw-Hill. Jonsen, A.R., M. Siegler, and W.T. Winslade. 1998. Clinical ethics: A practical approach to ethical decisions in clinical medicine, 4th ed. New York: McGraw-Hill.
go back to reference Keulartz, J., M. Schermer, M. Korthals, and T. Swierstra. 2004. Ethics in technological culture: A programmatic proposal for a pragmatist approach. Science, Technology and Human Values 29(1): 3–29.CrossRef Keulartz, J., M. Schermer, M. Korthals, and T. Swierstra. 2004. Ethics in technological culture: A programmatic proposal for a pragmatist approach. Science, Technology and Human Values 29(1): 3–29.CrossRef
go back to reference Larriviere, D., M.A. Williams, M. Rizzo, and R.J. Bonnie. 2009. Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology 73(17): 1406–1412.CrossRef Larriviere, D., M.A. Williams, M. Rizzo, and R.J. Bonnie. 2009. Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology 73(17): 1406–1412.CrossRef
go back to reference Launis, V. 2010. Cosmetic neurology: Sliding down the slippery slope? Cambridge Quarterly of Healthcare Ethics 19(2): 218–229.CrossRef Launis, V. 2010. Cosmetic neurology: Sliding down the slippery slope? Cambridge Quarterly of Healthcare Ethics 19(2): 218–229.CrossRef
go back to reference Lucke, J., S. Bell, B. Partridge, and W. Hall. 2010. Weak evidence for large claims contribute to the phantom debate Response. Biosocieties 5(4): 482–483.CrossRef Lucke, J., S. Bell, B. Partridge, and W. Hall. 2010. Weak evidence for large claims contribute to the phantom debate Response. Biosocieties 5(4): 482–483.CrossRef
go back to reference Lucke, J., S. Bell, B. Partridge, and W. Hall. 2011. Deflating the neuroenhancement bubble. AJOB Neuroscience 2(4): 38–43.CrossRef Lucke, J., S. Bell, B. Partridge, and W. Hall. 2011. Deflating the neuroenhancement bubble. AJOB Neuroscience 2(4): 38–43.CrossRef
go back to reference Lucke, J., B. Partridge, and W. Hall. 2012. Dealing with ennui: To what extent is “cognitive enhancement” a form of self-medication for symptoms of depression? AJOB Neuroscience 4(1): 17.CrossRef Lucke, J., B. Partridge, and W. Hall. 2012. Dealing with ennui: To what extent is “cognitive enhancement” a form of self-medication for symptoms of depression? AJOB Neuroscience 4(1): 17.CrossRef
go back to reference Mohamed, A.D., and B.J. Sahakian. 2012. The ethics of elective psychopharmacology. International Journal of Neuropsychopharmacology 15(4): 559–571.CrossRef Mohamed, A.D., and B.J. Sahakian. 2012. The ethics of elective psychopharmacology. International Journal of Neuropsychopharmacology 15(4): 559–571.CrossRef
go back to reference Nordmann, A. 2007. If and then: A critique of speculative nanoethics. Nanoethics 1(1): 31–46.CrossRef Nordmann, A. 2007. If and then: A critique of speculative nanoethics. Nanoethics 1(1): 31–46.CrossRef
go back to reference Oakley, J., and D. Cocking. 2005. Consequentialism, complacency, and slippery slope arguments. Theoretical Medicine and Bioethics 26(3): 227–239.CrossRef Oakley, J., and D. Cocking. 2005. Consequentialism, complacency, and slippery slope arguments. Theoretical Medicine and Bioethics 26(3): 227–239.CrossRef
go back to reference Outram, S. 2010a. Negotiating an inevitable future? AJOB Neuroscience 1(1): 29–31.CrossRef Outram, S. 2010a. Negotiating an inevitable future? AJOB Neuroscience 1(1): 29–31.CrossRef
go back to reference Outram, S. 2010b. The use of methylphenidate among students: The future of enhancement? Journal of Medical Ethics 36(4): 198–202.CrossRef Outram, S. 2010b. The use of methylphenidate among students: The future of enhancement? Journal of Medical Ethics 36(4): 198–202.CrossRef
go back to reference Outram, S. 2012. Ethical considerations in the framing of the cognitive enhancement debate. Neuroethics 5(2): 173–184.CrossRef Outram, S. 2012. Ethical considerations in the framing of the cognitive enhancement debate. Neuroethics 5(2): 173–184.CrossRef
go back to reference Outram, S., and E. Racine. 2011a. Examining reports and policies on cognitive enhancement: Approaches, rationale, and recommendations. Accountability in Research 18(5): 323–341. Outram, S., and E. Racine. 2011a. Examining reports and policies on cognitive enhancement: Approaches, rationale, and recommendations. Accountability in Research 18(5): 323–341.
go back to reference Outram, S., and E. Racine. 2011b. Public health ethics approaches to cognitive enhancement: Current models and points to consider. Public Health Ethics 4(1): 93–105.CrossRef Outram, S., and E. Racine. 2011b. Public health ethics approaches to cognitive enhancement: Current models and points to consider. Public Health Ethics 4(1): 93–105.CrossRef
go back to reference Parens, E. 2005. Authenticity and ambivalence: Toward understanding the enhancement debate. Hastings Center Report 35(3): 34–41.CrossRef Parens, E. 2005. Authenticity and ambivalence: Toward understanding the enhancement debate. Hastings Center Report 35(3): 34–41.CrossRef
go back to reference Parens, E. (ed.). 1998. Enhancing human traits: Ethical and social implications. Washington, D.C.: Georgetown University Press. Parens, E. (ed.). 1998. Enhancing human traits: Ethical and social implications. Washington, D.C.: Georgetown University Press.
go back to reference Parens, E., and J. Johnston. 2007. Does it make sense to speak of neuroethics? Three problems with keying ethics to hot new science and technology. EMBO Reports 8 Spec No: S61–S64. Parens, E., and J. Johnston. 2007. Does it make sense to speak of neuroethics? Three problems with keying ethics to hot new science and technology. EMBO Reports 8 Spec No: S61–S64.
go back to reference Partridge, B., S. Bell, J. Lucke, S. Yeates, and W. Hall. 2011. Smart drugs “as common as coffee”: Media hype about neuroenhancement. PLoS ONE 6(11): e28416.CrossRef Partridge, B., S. Bell, J. Lucke, S. Yeates, and W. Hall. 2011. Smart drugs “as common as coffee”: Media hype about neuroenhancement. PLoS ONE 6(11): e28416.CrossRef
go back to reference Racine, E. 2010. Pragmatic neuroethics: Improving treatment and understanding of the mind-brain. In Basic Bioethics, ed. G. McGee, and A. Caplan. Cambridge: MIT Press. Racine, E. 2010. Pragmatic neuroethics: Improving treatment and understanding of the mind-brain. In Basic Bioethics, ed. G. McGee, and A. Caplan. Cambridge: MIT Press.
go back to reference Racine, E. 2008. Which naturalism for bioethics? A defense of moderate pragmatic naturalism. Bioethics 22(2): 92–100.CrossRef Racine, E. 2008. Which naturalism for bioethics? A defense of moderate pragmatic naturalism. Bioethics 22(2): 92–100.CrossRef
go back to reference Racine, E., and C. Forlini. 2010a. Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Ethics blind spots in current debates. Neuroethics 3(1): 1–4.CrossRef Racine, E., and C. Forlini. 2010a. Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Ethics blind spots in current debates. Neuroethics 3(1): 1–4.CrossRef
go back to reference Racine, E., and C. Forlini. 2010b. Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology 74(19): 1555–1556. author reply 1556.CrossRef Racine, E., and C. Forlini. 2010b. Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology 74(19): 1555–1556. author reply 1556.CrossRef
go back to reference Racine, E., and J. Illes. 2006. Neuroethical responsibilities. Canadian Journal of Neurological Sciences 33(3): 269–277. Racine, E., and J. Illes. 2006. Neuroethical responsibilities. Canadian Journal of Neurological Sciences 33(3): 269–277.
go back to reference Ragan, C.I., I. Bard, and I. Singh. 2013. What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology 64: 588–595.CrossRef Ragan, C.I., I. Bard, and I. Singh. 2013. What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology 64: 588–595.CrossRef
go back to reference Repantis, D., P. Schlattmann, O. Lainsey, and I. Heuser. 2008. Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis Praxis 6: 139–174.CrossRef Repantis, D., P. Schlattmann, O. Lainsey, and I. Heuser. 2008. Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis Praxis 6: 139–174.CrossRef
go back to reference Repantis, D., O. Laisney, and I. Heuser. 2010a. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research 61(6): 473–481.CrossRef Repantis, D., O. Laisney, and I. Heuser. 2010a. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research 61(6): 473–481.CrossRef
go back to reference Repantis, D., P. Schlattmann, O. Laisney, and I. Heuser. 2010b. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research 62(3): 187–206.CrossRef Repantis, D., P. Schlattmann, O. Laisney, and I. Heuser. 2010b. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research 62(3): 187–206.CrossRef
go back to reference Roache, R. 2008. Ethics, speculation, and values. Nanoethics 2(3): 317–327.CrossRef Roache, R. 2008. Ethics, speculation, and values. Nanoethics 2(3): 317–327.CrossRef
go back to reference Sherwin, S. 1999. Foundations, frameworks, lenses: The role of theories in bioethics. Bioethics 13(3–4): 198–205. Sherwin, S. 1999. Foundations, frameworks, lenses: The role of theories in bioethics. Bioethics 13(3–4): 198–205.
go back to reference Tone, A. 2005. Listening to the past: History, psychiatry, and anxiety. Canadian Journal of Psychiatry 50(7): 373–380. Tone, A. 2005. Listening to the past: History, psychiatry, and anxiety. Canadian Journal of Psychiatry 50(7): 373–380.
go back to reference Toulmin, S. 1982. How medicine saved the life of ethics. Perspectives in Biology and Medicine 25(4): 736–750. Toulmin, S. 1982. How medicine saved the life of ethics. Perspectives in Biology and Medicine 25(4): 736–750.
go back to reference Van der Wilt, G.J., R. Reuzel, and H.D. Banta. 2000. The ethics of assessing health technologies. Theoretical Medicine and Bioethics 21(1): 103–115. Van der Wilt, G.J., R. Reuzel, and H.D. Banta. 2000. The ethics of assessing health technologies. Theoretical Medicine and Bioethics 21(1): 103–115.
go back to reference Vrecko, S. 2010. Neuroscience, power and culture: An introduction. History of the Human Sciences 23(1): 1–10.CrossRef Vrecko, S. 2010. Neuroscience, power and culture: An introduction. History of the Human Sciences 23(1): 1–10.CrossRef
go back to reference Wolf, S.M. 1994. Shifting paradigms in bioethics and health law: The rise of a new pragmatism. American Journal of Law and Medicine 20(4): 395–415. Wolf, S.M. 1994. Shifting paradigms in bioethics and health law: The rise of a new pragmatism. American Journal of Law and Medicine 20(4): 395–415.
go back to reference Wolraich, M., L. Brown, R.T. Brown, G. DuPaul, M. Earls, H.M. Feldman, T.G. Ganiats, B. Kaplanek, B. Meyer, J. Perrin, K. Pierce, M. Reiff, M.T. Stein, and S. Visser. 2011. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128(5): 1007–1022.CrossRef Wolraich, M., L. Brown, R.T. Brown, G. DuPaul, M. Earls, H.M. Feldman, T.G. Ganiats, B. Kaplanek, B. Meyer, J. Perrin, K. Pierce, M. Reiff, M.T. Stein, and S. Visser. 2011. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128(5): 1007–1022.CrossRef
go back to reference Zoloth, L. 2007. Mistakenness and the nature of the “post”: The ethics and the inevitability of error in theoretical work. Israel Affairs 13(4): 757–773.CrossRef Zoloth, L. 2007. Mistakenness and the nature of the “post”: The ethics and the inevitability of error in theoretical work. Israel Affairs 13(4): 757–773.CrossRef
Metadata
Title
The value and pitfalls of speculation about science and technology in bioethics: the case of cognitive enhancement
Authors
Eric Racine
Tristana Martin Rubio
Jennifer Chandler
Cynthia Forlini
Jayne Lucke
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
Medicine, Health Care and Philosophy / Issue 3/2014
Print ISSN: 1386-7423
Electronic ISSN: 1572-8633
DOI
https://doi.org/10.1007/s11019-013-9539-4

Other articles of this Issue 3/2014

Medicine, Health Care and Philosophy 3/2014 Go to the issue